DK3705488T3 - Neuroaktive steroider, sammensætninger og anvendelse heraf - Google Patents
Neuroaktive steroider, sammensætninger og anvendelse heraf Download PDFInfo
- Publication number
- DK3705488T3 DK3705488T3 DK20171670.1T DK20171670T DK3705488T3 DK 3705488 T3 DK3705488 T3 DK 3705488T3 DK 20171670 T DK20171670 T DK 20171670T DK 3705488 T3 DK3705488 T3 DK 3705488T3
- Authority
- DK
- Denmark
- Prior art keywords
- compositions
- neuroactive steroids
- neuroactive
- steroids
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 150000003431 steroids Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
- C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
- C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2014078820 | 2014-05-29 | ||
EP15799762.8A EP3149018B1 (en) | 2014-05-29 | 2015-05-29 | Neuroactive steroids, compositions, and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3705488T3 true DK3705488T3 (da) | 2022-10-03 |
Family
ID=54698130
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK15799762.8T DK3149018T3 (da) | 2014-05-29 | 2015-05-29 | Neuroaktive steroider, sammensætninger og anvendelse deraf |
DK20171670.1T DK3705488T3 (da) | 2014-05-29 | 2015-05-29 | Neuroaktive steroider, sammensætninger og anvendelse heraf |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK15799762.8T DK3149018T3 (da) | 2014-05-29 | 2015-05-29 | Neuroaktive steroider, sammensætninger og anvendelse deraf |
Country Status (26)
Country | Link |
---|---|
US (5) | US20180179247A1 (da) |
EP (3) | EP4144746A1 (da) |
JP (4) | JP6652934B2 (da) |
KR (3) | KR20240066304A (da) |
CN (3) | CN114369135A (da) |
AR (2) | AR100691A1 (da) |
AU (4) | AU2015266447A1 (da) |
CA (1) | CA2949720A1 (da) |
CY (1) | CY1124109T1 (da) |
DK (2) | DK3149018T3 (da) |
ES (2) | ES2805598T3 (da) |
HR (2) | HRP20221294T1 (da) |
HU (2) | HUE059829T2 (da) |
IL (3) | IL248948B (da) |
JO (1) | JO3691B1 (da) |
LT (2) | LT3149018T (da) |
MX (4) | MX2016015532A (da) |
PH (1) | PH12016502342A1 (da) |
PL (2) | PL3149018T3 (da) |
PT (2) | PT3149018T (da) |
RS (2) | RS60529B1 (da) |
RU (2) | RU2699359C2 (da) |
SG (2) | SG10201803812TA (da) |
SI (2) | SI3149018T1 (da) |
TW (1) | TW201625661A (da) |
WO (1) | WO2015180679A1 (da) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006318349B2 (en) | 2005-11-28 | 2010-08-19 | Marinus Pharmaceuticals | Ganaxolone formulations and methods for the making and use thereof |
ES2738526T3 (es) | 2011-10-14 | 2020-01-23 | Sage Therapeutics Inc | Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos |
US20160068563A1 (en) | 2013-04-17 | 2016-03-10 | Boyd L. Harrison | 19-nor neuroactive steroids and methods of use thereof |
WO2014169831A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
SG11201508550XA (en) | 2013-04-17 | 2015-11-27 | Sage Therapeutics Inc | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof |
CA2909546C (en) | 2013-04-17 | 2019-01-22 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
SI3021852T1 (sl) | 2013-07-19 | 2021-07-30 | Sage Therapeutics, Inc. | Nevroaktivni steroidi, sestavki in uporabe le-teh |
EP3035940B1 (en) | 2013-08-23 | 2018-10-17 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
SG10201803812TA (en) * | 2014-05-29 | 2018-06-28 | Sage Therapeutics Inc | Neuroactive steroids, compositions, and uses thereof |
WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
SG10202009861SA (en) | 2014-10-16 | 2020-11-27 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
PL3206493T3 (pl) | 2014-10-16 | 2021-01-25 | Sage Therapeutics, Inc. | Kompozycje i sposoby leczenia zaburzeń OUN |
LT3224269T (lt) | 2014-11-27 | 2020-07-10 | Sage Therapeutics, Inc. | Kompozicijos ir būdai, skirti cns sutrikimams gydyti |
PL3250210T3 (pl) | 2015-01-26 | 2021-07-26 | Sage Therapeutics, Inc. | Kompozycje i sposoby leczenia zaburzeń OUN |
DK3258939T3 (da) | 2015-02-20 | 2022-12-12 | Sage Therapeutics Inc | Neuroaktive steroider, sammensætninger og anvendelser heraf |
CA3001722A1 (en) | 2015-10-16 | 2017-04-20 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
MA43815A (fr) * | 2016-03-08 | 2021-04-07 | Sage Therapeutics Inc | Stéroïdes neuroactifs, compositions, et leurs utilisations |
CN116162121A (zh) * | 2016-07-11 | 2023-05-26 | 萨奇治疗股份有限公司 | C17、c20和c21取代的神经活性类固醇及其使用方法 |
US20190233465A1 (en) | 2016-07-11 | 2019-08-01 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
MX2019001669A (es) | 2016-08-11 | 2019-09-27 | Ovid Therapeutics Inc | Metodos y composiciones para el tratamiento de trastornos epilepticos. |
US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
WO2019113494A1 (en) | 2017-12-08 | 2019-06-13 | Sage Therapeutics, Inc. | Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders |
CA3090724A1 (en) * | 2018-02-11 | 2019-08-15 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Steroid derivative regulators, method for preparing the same, and uses thereof |
CN109503694A (zh) * | 2018-11-21 | 2019-03-22 | 苏州闻天医药科技有限公司 | 一种新型gabaa受体调节剂及其用途 |
US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
CA3124703C (en) * | 2019-01-14 | 2023-10-17 | Beijing Xuanyi Pharmasciences Co., Ltd. | Tetrazolone substituted steroids and use thereof |
MX2021014515A (es) | 2019-05-31 | 2022-03-22 | Sage Therapeutics Inc | Esteroides neuroactivos y composiciones de estos. |
WO2021026124A1 (en) | 2019-08-05 | 2021-02-11 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treatment of status epilepticus |
KR20220066262A (ko) | 2019-08-07 | 2022-05-24 | 상하이 한서 바이오메디컬 컴퍼니 리미티드 | 스테로이드 유도체 조절제의 염 및 결정형 |
US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
JP2023503928A (ja) | 2019-12-06 | 2023-02-01 | マリナス ファーマシューティカルズ, インコーポレイテッド | 結節性硬化症の治療での使用のためのガナキソロン |
US20240122945A1 (en) | 2021-01-28 | 2024-04-18 | Sage Therapeutics, Inc. | Use of neuroactive steroids for treatment of sexual dysfunction |
BR112024001518A2 (pt) * | 2021-07-28 | 2024-04-30 | Sage Therapeutics Inc | Formas cristalinas de um esteroide neuroativo |
WO2023164387A1 (en) | 2022-02-28 | 2023-08-31 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of gastrointestinal diseases or conditions |
WO2024026337A1 (en) | 2022-07-27 | 2024-02-01 | Sage Therapeutics, Inc. | Crystalline forms of a neuroactive steroid |
WO2024059608A1 (en) | 2022-09-15 | 2024-03-21 | Sage Therapeutics, Inc. | Deuterated neuroactive steroids |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3634717A1 (de) * | 1986-10-11 | 1988-04-14 | Dynamit Nobel Ag | Verfahren zur herstellung von 5-methyltetrazol |
US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
FR2679263B1 (fr) * | 1991-07-15 | 1994-01-14 | Staubli Ets | Perfectionnements aux ratieres a double leve du type hattersley pour machines a tisser. |
US5939545A (en) * | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
DE69518509T2 (de) * | 1994-02-14 | 2001-04-19 | Euro Celtique Sa | Androstane und pregnane zur allosterischen modulation des gaba-rezeptors |
WO1998005337A1 (en) * | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
UA73736C2 (en) * | 1999-04-29 | 2005-09-15 | Euro Celtic S A | Method for alleviating or preventing insomnia and inducing anesthesia |
WO2004036372A2 (en) * | 2002-10-15 | 2004-04-29 | Medtronic Inc. | Scoring of sensed neurological signals for use with a medical device system |
US7729773B2 (en) * | 2005-10-19 | 2010-06-01 | Advanced Neuromodualation Systems, Inc. | Neural stimulation and optical monitoring systems and methods |
ES2738526T3 (es) * | 2011-10-14 | 2020-01-23 | Sage Therapeutics Inc | Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos |
SG10201803812TA (en) * | 2014-05-29 | 2018-06-28 | Sage Therapeutics Inc | Neuroactive steroids, compositions, and uses thereof |
PL3206493T3 (pl) * | 2014-10-16 | 2021-01-25 | Sage Therapeutics, Inc. | Kompozycje i sposoby leczenia zaburzeń OUN |
-
2015
- 2015-05-29 SG SG10201803812TA patent/SG10201803812TA/en unknown
- 2015-05-29 EP EP22187660.0A patent/EP4144746A1/en active Pending
- 2015-05-29 DK DK15799762.8T patent/DK3149018T3/da active
- 2015-05-29 EP EP15799762.8A patent/EP3149018B1/en active Active
- 2015-05-29 EP EP20171670.1A patent/EP3705488B1/en active Active
- 2015-05-29 LT LTEP15799762.8T patent/LT3149018T/lt unknown
- 2015-05-29 IL IL248948A patent/IL248948B/en unknown
- 2015-05-29 PT PT157997628T patent/PT3149018T/pt unknown
- 2015-05-29 MX MX2016015532A patent/MX2016015532A/es unknown
- 2015-05-29 AU AU2015266447A patent/AU2015266447A1/en not_active Abandoned
- 2015-05-29 SG SG11201609813XA patent/SG11201609813XA/en unknown
- 2015-05-29 HU HUE20171670A patent/HUE059829T2/hu unknown
- 2015-05-29 WO PCT/CN2015/080216 patent/WO2015180679A1/en active Application Filing
- 2015-05-29 SI SI201531252T patent/SI3149018T1/sl unknown
- 2015-05-29 JP JP2016569716A patent/JP6652934B2/ja active Active
- 2015-05-29 AR ARP150101717A patent/AR100691A1/es active IP Right Grant
- 2015-05-29 KR KR1020247014858A patent/KR20240066304A/ko active Search and Examination
- 2015-05-29 US US15/314,565 patent/US20180179247A1/en active Pending
- 2015-05-29 CA CA2949720A patent/CA2949720A1/en active Pending
- 2015-05-29 RS RS20200799A patent/RS60529B1/sr unknown
- 2015-05-29 RS RS20220848A patent/RS63554B1/sr unknown
- 2015-05-29 KR KR1020167036320A patent/KR102494061B1/ko active IP Right Grant
- 2015-05-29 TW TW104117532A patent/TW201625661A/zh unknown
- 2015-05-29 PL PL15799762T patent/PL3149018T3/pl unknown
- 2015-05-29 HU HUE15799762A patent/HUE050028T2/hu unknown
- 2015-05-29 IL IL292461A patent/IL292461B2/en unknown
- 2015-05-29 RU RU2016151727A patent/RU2699359C2/ru active
- 2015-05-29 CN CN202110905603.6A patent/CN114369135A/zh active Pending
- 2015-05-29 ES ES15799762T patent/ES2805598T3/es active Active
- 2015-05-29 IL IL304033A patent/IL304033A/en unknown
- 2015-05-29 HR HRP20221294TT patent/HRP20221294T1/hr unknown
- 2015-05-29 DK DK20171670.1T patent/DK3705488T3/da active
- 2015-05-29 PT PT201716701T patent/PT3705488T/pt unknown
- 2015-05-29 PL PL20171670.1T patent/PL3705488T3/pl unknown
- 2015-05-29 LT LTEP20171670.1T patent/LT3705488T/lt unknown
- 2015-05-29 CN CN202111131937.9A patent/CN114133423A/zh active Pending
- 2015-05-29 KR KR1020237003114A patent/KR102664412B1/ko active IP Right Grant
- 2015-05-29 ES ES20171670T patent/ES2927007T3/es active Active
- 2015-05-29 RU RU2019126637A patent/RU2019126637A/ru unknown
- 2015-05-29 SI SI201531879T patent/SI3705488T1/sl unknown
- 2015-05-29 CN CN201580039652.9A patent/CN106661078A/zh active Pending
- 2015-05-31 JO JOP/2015/0132A patent/JO3691B1/ar active
-
2016
- 2016-11-24 PH PH12016502342A patent/PH12016502342A1/en unknown
- 2016-11-25 MX MX2021005106A patent/MX2021005106A/es unknown
- 2016-11-25 MX MX2021005099A patent/MX2021005099A/es unknown
- 2016-11-25 MX MX2023004352A patent/MX2023004352A/es unknown
-
2019
- 2019-12-09 AU AU2019279910A patent/AU2019279910B2/en active Active
-
2020
- 2020-01-24 JP JP2020009771A patent/JP6892936B2/ja active Active
- 2020-01-31 US US16/778,975 patent/US20200165291A1/en not_active Abandoned
- 2020-07-17 HR HRP20201126TT patent/HRP20201126T1/hr unknown
- 2020-07-27 CY CY20201100683T patent/CY1124109T1/el unknown
- 2020-11-10 US US17/094,783 patent/US20210061849A1/en not_active Abandoned
- 2020-11-13 US US17/097,569 patent/US20210061850A1/en not_active Abandoned
-
2021
- 2021-03-25 AR ARP210100747A patent/AR121661A2/es unknown
- 2021-05-28 JP JP2021089953A patent/JP7386204B2/ja active Active
- 2021-06-28 AU AU2021204410A patent/AU2021204410B2/en active Active
-
2023
- 2023-07-10 JP JP2023113247A patent/JP2023123878A/ja active Pending
- 2023-10-06 US US18/482,079 patent/US20240076310A1/en active Pending
- 2023-12-19 AU AU2023285755A patent/AU2023285755A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL292461A (en) | Neuroactive steroids, preparations and their uses | |
IL285703A (en) | Neuroactive steroids, preparations and their uses | |
DK3258939T3 (da) | Neuroaktive steroider, sammensætninger og anvendelser heraf | |
DK3021852T3 (da) | Neuroaktive steroider, sammensætninger og anvendelser deraf | |
DK3488852T3 (da) | Neuroaktive steroider, sammensætninger og anvendelser deraf | |
DK3210977T3 (da) | Hidtil ukendt aminoalkylbenzothiazepinderivat og anvendelse deraf | |
DK3169741T3 (da) | Forbedrede bindemiddelsammensætninger og anvendelser deraf | |
DK3161124T3 (da) | Endofytter, associerede sammensætninger og fremgangsmåder til anvendelse deraf | |
DK3018183T3 (da) | Halogenolefinbaseret sammensætning og anvendelse deraf | |
DK3154594T3 (da) | Fap-aktiverede, terapeutiske midler og anvendelser i forbindelser dermed | |
DK3110441T3 (da) | Hidtil ukendt polysaccharid og anvendelser deraf | |
DK3218358T3 (da) | Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner | |
KR20180084891A (ko) | 구조 조성물 및 방법 | |
DK3161139T3 (da) | Tlr-4-specifikke aptamerer og anvendelser heraf | |
DK3148584T3 (da) | Kombination, der omfatter et glucocorticoid og edo-s101 | |
DK3223796T3 (da) | Farmaceutiske sammensætninger, fremstilling og anvendelser deraf | |
DK3365321T3 (da) | Solabegron-zwitterion og anvendelser deraf | |
DK3166960T3 (da) | Lav-substituerede polymyxiner og sammensætninger deraf | |
DK3235799T3 (da) | Oximforbindelse og herbicid | |
ITUB20156000A1 (it) | Composizione nematocida e suo utilizzo | |
DK3371324T3 (da) | Virusbiomarkører og anvendelser deraf | |
DK3099314T3 (da) | Tolerogene sammensætninger og anvendelser deraf | |
DK3191080T3 (da) | Parenterale sammensætninger og anvendelser deraf | |
DK3322733T3 (da) | Hide1-sammensætninger og fremgangsmåder | |
TH1601000561A (th) | สารกระจาย |